Semin Liver Dis 2000; 20(4): 465-480
DOI: 10.1055/s-2000-13156
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatitis B and C in the Liver Transplant Recipient

Hugo R. Rosen1 , Paul Martin2
  • 1Division of Gastroenterology/Hepatology and Liver Transplantation Program, Portland Veterans Administration, and Oregon Health Sciences University, Portland, Oregon
  • 2Division of Digestive Diseases and Dumont-UCLA Transplant Program, Center for Health Sciences, University of California at Los Angeles; Los Angeles, California
Further Information

Publication History

Publication Date:
31 December 2000 (online)

ABSTRACT

Liver disease related to chronic viral hepatitis is the leading indication for orthotopic liver transplantation (OLT) worldwide. The evolution of our understanding of hepatitis B and C infection in the OLT recipient has been rapid in the last decade. The spontaneous risk for viral recurrence after transplantation is high but has been effectively decreased in hepatitis B infected recipients with the use of HBIG and lamivudine with dramatic improvements in patient and graft survivals. HCV recurrence as defined by histologic injury is almost universal although graft or patient outcomes for the first decade after OLT do not appear to be limited by HCV infection for most patients. However, individual patients do suffer severe graft injury and even graft loss due to recurrent HCV. With longer follow up into the second decade, the prevalence of HCV-related graft failure is likely to increase. In addition, the role of different immunosuppressive protocols on disease recurrence requires further study. Thus, although hepatitis B recurrence has been effectively contained by use of HBIG with or without lamivudine, the more intractable problem of managing recurrent HCV has as yet no obvious solutions. Optimal antiviral strategies for hepatitis C post-OLT have yet to be identified.

REFERENCES

  • 1 Todo S, Demetris A, Van Thiel D. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease.  Hepatology . 1991;  13 619
  • 2 Terrault N A. Hepatitis B virus and liver transplantation.  Clini Liver Dis. 1999;  2 389-415
  • 3 Samuel D, Muller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
  • 4 Perrillo R, Rakela J, Martin P. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation.  Hepatology . 1997;  26 260A
  • 5 Tipples G, Ma M, Fischer K. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro.  Hepatology . 1996;  24 714
  • 6 Terrault N, Zhou S, McCory R W. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.  Hepatology . 1998;  28 555-559
  • 7 Ghany M, Ayola B, Villamil F, Gish R. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology . 1998;  27 213
  • 8 Chang M-H, Chen C-J, Lai M-S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.  N Engl J Med . 1997;  1855
  • 9 Terrault N, Pessoa M, Singleton S. Improved survival of hepatitis B patients undergoing liver transplantation: effects independent of therapeutic interventions.  Hepatology . 1997;  26 177A
  • 10 Davies S F, Portmann B C, O'Grady J G. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.  Hepatology . 1991;  13 150-155
  • 11 Chisari F, Klopchin K, Moriyama T. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.  Cell . 1989;  59 1145
  • 12 Mason A L, Wick M, White H M. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.  Gastroenterology . 1993;  4 1269-1270
  • 13 Charlton M, Seaberg E, Wiesner R. Predictors of patient and graft survival following liver transplantation for hepatitis C.  Hepatology . 1998;  28 823-830
  • 14 Samuel D, Muller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
  • 15 Jurim O, Martin P, Shaked A. Liver transplantation for chronic hepatitis B in Asians.  Transplantation . 1994;  9 1393-1395
  • 16 Ho B M, So S K, Esquivel C O, Keeffe E B. Liver transplantation in Asian patients with chronic hepatitis B.  Hepatology . 1997;  1 223-225
  • 17 So S K, Esquivel C O, Imperial J C. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?.  J Gastroenterol Hepatol . 1999;  28(Suppl) S48-S53
  • 18 Crippin J, Foster B, Carlen S. Retransplantation for hepatitis B - A multicenter experience.  Transplantaton . 1994;  6 823-826
  • 19 Ishitani M, McGory R, Dickson R. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft.  Transplantation . 1997;  3 410-414
  • 20 Roche B, Samuel D, Feray C. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.  Liver Transpl Surg . 1999;  3 166-174
  • 21 Omata M, Ehata T, Yokosuka O. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis.  N Engl J Med . 1991;  324 1699
  • 22 Belle S, Beringer K, Detre K. Long-term outcome of liver transplant recipients in the US.  Clinical Transplants . 1995;  19-31
  • 23 Naumann U, Protzer-Knolle U, Berg T. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis.  Hepatology . 1997;  2 478-484
  • 24 Ottobrelli A, Marzano A, Smedile A. Patterns of hepatitis delta virus reinfection and disease in liver transplantation.  Gastroenterology . 1991;  101 1649-1654
  • 25 Huang E J, Wright T L, Lake J R, Combs C, Ferrell L D. Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation.  Hepatology . 1996;  3 396-404
  • 26 Pessoa M, Kim E, Martin P. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin in reducing the incidence of acute rejection post transplantation.  Gastroenterology . 1998;  114 A1322
  • 27 Samuel D, Zignego A, Reynes M. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.  Hepatology . 1995;  21 333
  • 28 Smedile A, Casey J L, Cote P J, Durazzo M, Lavezzo B, Purcell R H, Rizzetto M, Gerin J L. Hepatitis D Viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope.  Hepatology . 1998;  6 1723-1729
  • 29 Alberti A, Pontisso P, Chemello L. The interaction between hepatitis B and hepatitis C virus in acute and chronic liver disease.  J Hepatology . 1995;  2(Suppl) 38-41
  • 30 Feray C, Gigou M, Samuel D. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation.  Ann Intern Med . 1998;  10 810-816
  • 31 Dickson R C, Everhart J E, Lake J R. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen.  Gastroenterology . 1997;  5 1668-1674
  • 32 Uemoto S, Sugiyama K, Marusawa H. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants.  Transplantation . 1998;  4 494-499
  • 33 Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M E, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med . 1999;  341 22-26
  • 34 Dodson S F, Issa S, Araya V. Infectivity of hepatic allografts with antibodies to hepatitis B virus.  Transplantation . 1997;  11 1582-1584
  • 35 Crespo J, Fabrega E, Casafont F. Severe clinical course of de novo hepatitis B infection after liver transplantation.  Liver Transpl Surg . 1999;  3 175-183
  • 36 Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med . 1996;  11 693-699
  • 37 Wong P Y, McPeake J R, Portmann B. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma.  Am J Gastroenterol . 1995;  1 29-34
  • 38 Mazzaferro V, Regalia E, Montalto F. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence.  Liver . 1996;  2 117-122
  • 39 Berenguer M, Wright T L. Antiviral therapy before and after liver transplantation. In: Sorrell M, Maddrey WC, eds. Liver Transplantation (3rd ed); (in press)
  • 40 Terrault N A, Combs H C, Ferrel L. Interferon alpha for recurrent hepatitis B infection after liver transplantation.  Liver Transpl Surg . 1996;  2 132-138
  • 41 Bain V G, Kneteman N M, Ma M M. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation.  Transplantation . 1996;  62 1456-1462
  • 42 Perrillo R, Rakela J, Dienstaag J. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.  Hepatology . 1999;  29 1581-1586
  • 43 Fontana R J, Keeffe E B, Han S. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients.  Hepatology . 1999;  30 301A
  • 44 Mutimer D, Pillay D, Shields P. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient.  Gut . 2000;  46 107-113
  • 45 Villeneuve J P, Condreay L D, Willems B. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology . 2000;  31 207-210
  • 46 Markowitz J S, Martin P, Conrad A J. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.  Hepatology . 1998;  28 585-589
  • 47 Yao F Y, Osorio R W, Roberts J P. Intramuscular hepatitis B immune globulin continued with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.  Liver Transpl Surg . 1999;  5 491-496
  • 48 Sanchez-Fueyo A, Rimola A, Grande L. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.  Hepatology . 2000;  31 496-501
  • 49 Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections.  Gastroenterology . 2000;  118 S83-S103
  • 50 Alter M J. The epidemiology of acute and chronic hepatitis C.  Clin Liver Dis . 1997;  1 559-568
  • 51 Gane E. Hepatitis C virus infection following liver transplantation.  Viral Hepat Rev . 1998;  4 97-125
  • 52 Rosen H R, Gretch D R. Hepatitis C virus: molecular aspects and implications for future therapy.  Molecular Medicine Today . 1999;  5 393-399
  • 53 Koziel M J, Dudley D, Afdhal N. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.  J Virol . 1993;  67 7522-7532
  • 54 Ferrari C, Valli A, Galati L. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections.  Hepatology . 1994;  9 286-295
  • 55 Tong M J, El-Farra N A, Reikes A R. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med . 1995;  332 1463-1466
  • 56 Missale G, Bertoni R, Lamonaca V. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.  J Clin Invest . 1996;  98 706-714
  • 57 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
  • 58 Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients.  Gastroenterology . 1997;  112 463-472
  • 59 Gane E J, Naoumov N V, Qian K-P. A longitudinal analysis of hepatitis C virus replication following liver transplantation.  Gastroenterology . 1996;  110 167-177
  • 60 Fukumoto T, Berg T, Ku Y. Viral Dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.  Hepatology . 1996;  24 1351-1354
  • 61 Boker K, Dalley G, Bahr M. Long-term outcome of hepatitis C virus infection after liver transplantation.  Hepatology . 1997;  25 203-210
  • 62 Rosen H R, O'Reilly P M, Shackleton C R. Graft loss following liver transplantation in patients with chronic hepatitis C.  Transplantation . 1996;  62 1773-1776
  • 63 Gane E J, Portmann B C, Naoumouv N V. Long-term outcome of hepatitis C infection after liver transplantation.  N Eng J Med . 1996;  334 821-827
  • 64 Rosen H R, Gretch D R, Oehlke M. Timing and severity of hepatitis C recurrence following liver transplantation as predictors of longterm allograft injury.  Transplantation . 1998;  65 1178-1182
  • 65 Prieto M, Berenguer M, Rayon J M. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.  Hepatology . 1999;  29 250-256
  • 66 Dickson R C, Caldwell S H, Ishitani M B, Lau J YN, Driscoll C J, Stevenson W C. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation.  Transplantation . 1996;  61 701-705
  • 67 Schluger L K, Sheiner P A, Thung S N. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.  Hepatology . 1996;  23 971-976
  • 68 Chazouilleres O, Kim M, Combs C. Quantitation of hepatitis C virus RNA in liver transplant recipients.  Gastroenterology . 1994;  106 994-999
  • 69 Gretch D R, Bacchi C E, Corey L, delaRosa C, Lesniewski R R, Kowdley K, Gown A, Frank I, Perkins J D, Carithers R L. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features.  Hepatology . 1995;  22 1-9
  • 70 Feray C, Gigou M, Samuel D. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation.  Gastroenterology . 1995;  108 1088-1096
  • 71 Vargas H E, Laskus T, Wang L F. The influence of hepatitis C virus genotype on the outcome of liver transplantation.  Liver Transpl Surg . 1997;  4 22-27
  • 72 Zhou S, Terrault N A, Ferrell L, Hahn J A, Lau J YN, Simmonds P. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia.  J Hepatology . 1996;  24 1041-1046
  • 73 Shuhart M C, Bronner M P, Gretch D R. Histological and clinical outcome after liver transplantation for hepatitis C.  Hepatology . 1997;  26 1646-1652
  • 74 Gonzalez-Peralta R, Lau J YN. Do viral genotypes and HLA matching influence the outcome of recurrent hepatitis C virus infection after liver transplantation?.  Liver Transpl Surg . 1998;  4 104-108
  • 75 Berenguer M, Prieto M, Cordoba J. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.  J Hepatol . 1998;  28 756-763
  • 76 Gretch D R, Polyak S J, Wilson J J. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.  J Virology . 1996;  70 7622-7631
  • 77 Sullivan D G, Wilson J J, Carithers R L, Perkins J D, Gretch D R. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns.  J Virology . 1998;  72 10036-10043
  • 78 Ghobrial R M, Colquhoun S, Rosen H R. Tacrolimus versus cyclosporine immunosuppression in liver transplantation for hepatitis C.  Hepatology . 1998;  28 261A[abstract]
  • 79 Zervos X A, Weppler D, Fragulidis G P. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation.  Transplantation . 1998;  65 1044-1046
  • 80 Wiesner R H, and the United States FK506 Study Group. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation.  Transplantation . 1998;  66 493-499
  • 81 Martin P, Goldstein R M, Goss J. A prospective controlled trial of tacrolimus vs. cyclosporine in orthotopic liver transplant recipients with hepatitis C virus: lack of effect on recurrent hepatitis.  Hepatology . 1998;  28 313A
  • 82 Rosen H R, Martin P. Liver Transplantation. In: Schiff ER, Maddrey WC, Sorrell MF, eds. Schiff's Disorders of Liver Disease, 8th ed Philadelphia: Lippincott-Raven 1999: 1589-1615
  • 83 Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of NIDDK Liver Transplantation Database.  Liver Transpl Surg . 1999;  5 S107-S114
  • 84 Sheiner P A, Schwartz M E, Mor E. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.  Hepatology . 1995;  21 30-34
  • 85 Rosen H R, Shackleton C R, Farmer D A. Use of OKT3 (monoclonal antibody) associated with early and severe hepatitis C recurrence following liver transplantation.  Am J Gastroenterol . 1997;  92 1453-1456
  • 86 Rosen H R, Martin P. OKT3 and hepatitis C: Defining the risks.  Transplantation . 1997;  63 171-172
  • 87 Rosen H R, Chou S, Gretch D R. Cytomegalovirus viremia: risk factor for allograft cirrhosis following liver transplantation for hepatitis C.  Transplantation . 1997;  64 721-726
  • 88 Charlton M, Seaberg E C, Wiesner R H. Increased mortality following CMV infection in patients transplanted for HCV: results of the NIDDK liver transplantation database.  Hepatology . 1998;  4 345A
  • 89 Rosen H R, Hinrichs D J, Gretch D R. Association of Multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation.  Gastroenterology. 1999;  117 926-932 1012-1014
  • 90 Asanza C, Garcia-Monzon C, Clemente G. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation.  Hepatology . 1997;  26 755-763
  • 91 Gane E. The role of TNF-alpha in HCV recurrence following liver transplantation.  (in press).
  • 92 Rosen H R, Lentz J J, Rose S L. Donor polymorphism of tumor necrosis factor gene associated with variable severity of hepatitis C recurrence following liver transplantation.  Transplantation . 1999;  68 1898-1902
  • 93 Singh N, Gayowski T, Wagener M M, Marino I R. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis.  Transplantation . 1996;  61 402-406
  • 94 Negro F, Gijostra E, Rubbia-Brandt L. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.  J Med Virol . 1998;  56 224-229
  • 95 Crespo J, Carte B, Lozano J L. Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia.  Am J Gastro . 1997;  9 1458-1462
  • 96 Rosen H R, Gretch D R, Kaufman E, Quan S. The humoral immune response to hepatitis C following liver transplantation: assessment of a new immunoblot assay.  Am J Gastro (in press).
  • 97 Ishitani M, McGory R, Dickson R. Late hepatic artery thrombosis: a potential complication of viral hepatitis.  Hepatology . 1996;  24 293A
  • 98 Altraif I H, Abdulla A S, al Sebayel I M. Hepatitis C associated glomerulonephritis.  Am J Nephrol . 1995;  15 407-410
  • 99 Johnson L B, Edwards E, Rustgi V K, Plotkin J S, Kuo P C. Impact of donor hepatitis C infection on recipient outcome following liver transplantation in the hepatitis C positive recipient: an analysis of the UNOS data.  Hepatology . 1998;  28 388A
  • 100 Vargas H E, Laskus T, Wang L-F. Outcome of liver transplantation in hepatitis C virus-infected grafts.  Gastroenterology . 1999;  117 149-155
  • 101 Rosen H R, Martin P. Hepatitis C infection in patients undergoing liver retransplantation.  Transplantation . 1998;  66 1612-1616
  • 102 Casavilla F A, Lee R, Lim J, Kramer D. Outcome of liver retransplantation for recurrent hepatitis C infection.  Hepatology . 1995;  22 153A
  • 103 Feray C, Habsanne A, Samuel D. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus.  J Hepatology . 1995;  22 135A
  • 104 Carithers R L. Recurrent hepatitis C after liver transplantation.  Liver Transpl Surg . 1997;  3 S16-S19
  • 104b Rosen H R. Retransplantation for hepatitis C: implications of different policies.  Liver Transpl . 2000;  6 41S-46S
  • 105 Berenguer M, Wright T L. Treatment strategies for recurrent hepatitis C after liver transplantation.  Clin Liver Dis . 1998;  3 883-899
  • 106 Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis C virus infection after liver transplantation.  J Hepatol . 1999;  31(Suppl) 222-226
  • 107 Wright T L, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20 773-779
  • 108 Feray C, Samuel D, Gigou M. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection.  Hepatology . 1995;  22 1084-1089
  • 109 Gane E J, Lo S K, Riordan S M. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation.  Hepatology . 1998;  27 1403-1407
  • 110 Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients.  N Engl J Med . 1994;  330 1160-1161
  • 111 Cattral M S, Hemming A W, Wanless I R. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.  Transplantation . 1999;  67 1277-1280
  • 112 Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.  Hepatology . 1997;  26 500-504
  • 113 Lavezzo B, Leone N, Smedile A. Combination therapy of interferon alpha 2-b and ribavirin for recurrent hepatitis C after liver transplantation.  J Hepatol . 1999;  30(Suppl 1) 67
  • 114 Gopal D, Rabkin J M, Berk B. Treatment of progressive HCV recurrence following liver transplatation with combination interferon and ribavirin therapy.  (in press).
  • 115 Sheiner P, Boros O, Klion F M. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.  Hepatology . 1998;  28 831-838
  • 116 Reddy K R, Weppler D, Zervos X A. Recurrent HCV infection following OLTX.  Hepatology . 1996;  24(Suppl) 295A
  • 117 Singh N, Gayowski T, Wannstedt C. Interferon-a for prophylaxis of recurrent hepatitis C in liver transplant recipients.  Transplantation . 1998;  65 82-86
  • 118 Mazzaferro V, Regalia E, Pulvirenti A. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.  Transplant Proc . 1997;  29 519-521
  • 119 Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues.  J Viral Hepat . 2000;  7 87-92
  • 120 Feray C, Caccamo L, Alexander G J. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.  Gastroenterology . 1999;  117 619-625
  • 121 Gayowski T, Singh N, Keyes L. Late-onset renal failure after liver transplantation: role of posttransplant alcohol use.  Transplantation . 2000;  69 383-388
  • 122 Paterson D L, Gayowski T, Wannstedt C F. Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis.  Clin Transpl . 2000;  14 48-54